Pfizer: Lymphoma, Large B-Cell, Diffuse trials
The registry lists 25 Lymphoma, Large B-Cell, Diffuse studies with Pfizer as lead sponsor. 0 are open to participants now and 11 have results posted.
Phase 1 13Phase 2 11Phase 3 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedNCT05626322Phase 1/2Results posted
- Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLActive, not recruitingNCT04404283Phase 3Results posted
- Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)TerminatedNCT02951156Phase 3Results posted
- Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaTerminatedNCT02855359Phase 2Results posted
- Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell LymphomaTerminatedNCT02594163Phase 2Results posted
- Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaTerminatedNCT02592876Phase 2Results posted
- Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT01925612Phase 2Results posted
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01421667Phase 2Results posted
- A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
- A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyTerminatedNCT01232556Phase 3Results posted
- Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00867087Phase 2Results posted
- A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersTerminatedNCT06870487Phase 1
- A Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersTerminatedNCT06254495Phase 1
- A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersTerminatedNCT06120504Phase 1
- A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.TerminatedNCT05896163Phase 1/2
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedNCT03530683Phase 1
- A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin LymphomaTerminatedNCT02702141Phase 1
- Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)WithdrawnNCT02653989Phase 2
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- Safety Study of SGN-CD70A in Cancer PatientsCompletedNCT02216890Phase 1
- A Safety Study of SGN-CD19A for B-Cell LymphomaCompletedNCT01786135Phase 1
- Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLCompletedNCT00655837Phase 1
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCLTerminatedNCT00529503Phase 2
- Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell LymphomaCompletedNCT00435916Phase 2